Biocompatible nanofibrous scaffolds incorporating titanium dioxide and melatonin to enhance osteogenesis in ADMSCs
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-07 · 399 (10) · 16567-16577
DOI: 10.1007/s00210-026-05155-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 05.05.2026. Verfasst von Niloofar MohammadEbrahim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Technology Research Center (STRC), Iran University of Medical Sciences (IUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Melatonin, Mesenchymal Stem Cells, Titanium, Osteogenesis. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Large bone defects remain a significant clinical challenge due to the limitations of autografts and allografts, prompting interest in bioactive scaffolds for bone tissue engineering. This study aimed to develop and evaluate electrospun nanofibrous scaffolds composed of polycaprolactone (PCL) and polylactic acid (PLA), incorporating titanium dioxide nanoparticles (TiO₂) and melatonin (Mel), to enhance their osteogenic differentiation potential. PCL/PLA, PCL/PLA/TiO₂, PCL/PLA/Mel, and PCL/PLA/TiO₂/Mel scaffolds were fabricated via electrospinning and characterized for morphology, fiber diameter, and mechanical properties. Biological performance was evaluated using adipose-derived mesenchymal stem cells (ADMSCs) through MTT assay, calcium content, alkaline phosphatase (ALP) activity, and osteogenic gene expression. TEM confirmed uniform TiO₂ nanoparticle distribution without agglomeration. All scaffolds exhibited continuous cylindrical fibers without defects. TiO₂ incorporation reduced tensile strength but increased elongation, while melatonin enhanced tensile strength. MTT assays confirmed biocompatibility and higher proliferation in TiO₂- and Mel-containing scaffolds. Calcium content and ALP activity were significantly higher in TiO₂- and/or Mel-modified scaffolds, with the PCL/PLA/TiO₂/Mel group showing the most significant osteogenic differentiation potential. Gene expression analysis revealed upregulated osteopontin, osteonectin, and osteocalcin in TiO₂- and Mel-containing scaffolds. Co-incorporation of TiO₂ nanoparticles and melatonin into electrospun PCL/PLA scaffolds synergistically enhances osteogenic differentiation and may serve as a promising strategy for bone tissue regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell Technology Research Center (STRC), Iran University of Medical Sciences (IUMS), Tehran, Iran.
- Department of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
- Stem Cell Technology Research Center (STRC), Iran University of Medical Sciences (IUMS), Tehran, Iran. esmaeili_elaheh@yahoo.com.
Zitieren
APA
MohammadEbrahim, N., Khalili, M., Rad, I., Mehrabadi, M., Noghlebari, N. A., Akhlaghpasand, M., Hajarizadeh, A., & Esmaeili, E. (2026). Biocompatible nanofibrous scaffolds incorporating titanium dioxide and melatonin to enhance osteogenesis in ADMSCs. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(10), 16567-16577. https://doi.org/10.1007/s00210-026-05155-6
Vancouver
MohammadEbrahim N, Khalili M, Rad I, Mehrabadi M, Noghlebari NA, Akhlaghpasand M, et al. Biocompatible nanofibrous scaffolds incorporating titanium dioxide and melatonin to enhance osteogenesis in ADMSCs. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(10):16567-16577. doi:10.1007/s00210-026-05155-6
BibTeX
@article{MohammadEbrahim2026,
author = {MohammadEbrahim, Niloofar and Khalili, Mahsa and Rad, Iman and Mehrabadi, Marzieh and Noghlebari, Nastaran Ansari and Akhlaghpasand, Mohammadhosein and Hajarizadeh, Atieh and Esmaeili, Elaheh},
title = {Biocompatible nanofibrous scaffolds incorporating titanium dioxide and melatonin to enhance osteogenesis in ADMSCs},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {10},
pages = {16567--16577},
doi = {10.1007/s00210-026-05155-6}
}
EUVIMED